These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31201013)

  • 1. Clinical Efficacy and Safety of Jinshuibao Combined With ACEI/ARB in the Treatment of Diabetic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials.
    Li Y; Xu G
    J Ren Nutr; 2020 Mar; 30(2):92-100. PubMed ID: 31201013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of seven Chinese patent medicines for early diabetic kidney disease: A Bayesian network meta-analysis.
    Zhao J; Ai J; Mo C; Shi W; Meng L
    Complement Ther Med; 2022 Aug; 67():102831. PubMed ID: 35398481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Ophiocordyceps sinensis (syn. Cordyceps sinensis) combined with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) versus ACEI/ARB alone in the treatment of diabetic kidney disease: a meta-analysis.
    Luo Y; Yang SK; Zhou X; Wang M; Tang D; Liu FY; Sun L; Xiao L
    Ren Fail; 2015 May; 37(4):614-34. PubMed ID: 25682973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of Salvia miltiorrhiza and ligustrazine injection combined with ACEI/ARB on diabetic kidney disease: A systematic review and meta-analysis.
    Zhang Z; Luo L; Li X; Zhong Y
    Medicine (Baltimore); 2024 Feb; 103(8):e35853. PubMed ID: 38394516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in diabetic nephropathy: a systematic review and meta-analysis.
    Du YH; Guan CJ; Li LY; Gan P
    Ann Palliat Med; 2022 Mar; 11(3):1093-1101. PubMed ID: 35365039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of Ophiocordyceps sinensis combined with ACEI/ARB on diabetic kidney disease: A systematic review and meta-analysis.
    Yan G; Chang T; Zhao Y; Yu M; Mi J; Wang G; Wang X; Liao X
    Phytomedicine; 2023 Jan; 108():154531. PubMed ID: 36375237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of Tripterygium wilfordii Hook in the treatment of diabetic kidney disease stage IV: A meta-analysis of randomized controlled trials.
    Ren D; Zuo C; Xu G
    Medicine (Baltimore); 2019 Mar; 98(11):e14604. PubMed ID: 30882626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Meta analysis of the efficacy and safety of combined treatment with ARB and ACEI on diabetic kidney disease].
    Gu J; Han L; Liu Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):623-30. PubMed ID: 23828705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of adding Rheum officinale to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal function in patients with chronic renal failure: A meta-analysis of randomized controlled trials
.
    Yang Y; Ma YP; Zhang Z; Dai PL; Li P; Li WG
    Clin Nephrol; 2018 Jun; 89(6):445-454. PubMed ID: 29208203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and safety of astragalus injection combined with ACEI/ARB in the treatment of diabetic kidney disease: Protocol for a systematic review and meta-analysis.
    Zhu Z; Zhang Q; Liu L; Bao P; Liu S; Song C; Yang W; Nan Z
    Medicine (Baltimore); 2022 Dec; 101(49):e31490. PubMed ID: 36626537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of traditional Chinese medicine and angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and sodium glucose cotransporter inhibitors in patients with diabetic kidney disease: A systematic review and network meta-analysis.
    Zhang L; Miao R; Yu T; Wei R; Tian F; Huang Y; Tong X; Zhao L
    Pharmacol Res; 2022 Mar; 177():106111. PubMed ID: 35183713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of astragalus combined with renin-angiotensin-aldosterone system blockers in the treatment of stage III diabetic nephropathy: a systematic review and meta-analysis.
    Lin YQ; Yu F; Chen HJ; Deng YR; Lin J; Xu Y; Zheng X; Zhang JW; Liu JF
    Ren Fail; 2024 Dec; 46(2):2359033. PubMed ID: 38836372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy.
    Ren F; Tang L; Cai Y; Yuan X; Huang W; Luo L; Zhou J; Zheng Y
    Ren Fail; 2015 May; 37(4):548-61. PubMed ID: 25707526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis.
    Tian ML; Shen Y; Sun ZL; Zha Y
    Int Urol Nephrol; 2015 May; 47(5):815-22. PubMed ID: 25862237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of tripterygium glycosides combined with ARB on diabetic nephropathy: a meta-analysis.
    Wu X; Huang Y; Zhang Y; He C; Zhao Y; Wang L; Gao J
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33057690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
    Liu X; Ma L; Li Z
    J Endocrinol Invest; 2020 Jul; 43(7):959-972. PubMed ID: 31939197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy, safety, and cost of nine Chinese patent medicines combined with ACEI/ARB in the treatment of early diabetic kidney disease: A network meta-analysis.
    Liu J; Zhang X; Xu G
    Front Pharmacol; 2022; 13():939488. PubMed ID: 36071841
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
    Ji Y; Yang K; Xiao B; Lin J; Zhao Q; Bhuva MS; Yang H
    J Cell Biochem; 2019 Mar; 120(3):3689-3695. PubMed ID: 30270542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.